Riskpilot← Back to searchSign inGet full accessAntibodypedia AB
ABActiveOrg 5568314305SolnaWeb search portal activities · NACE 6391Est. 20100 employees
Revenue 2025
SEK 3K
-96% vs 2024
EBITDA margin
-851.9%
-253% vs 2024
Equity ratio
99.3%
Financial strength
Net profit 2025
SEK -602
-102% vs 2024
| Revenue | SEK 3K | -96% |
| EBITDA | SEK -24K | -253% |
| Net profit | SEK -602 | -102% |
| Total assets | SEK 1,4M | +0% |
| Equity | SEK 1,4M | +0% |
| Employees | 0 | — |
Legal name
Antibodypedia AB
Org number
5568314305
Legal form
Aktiebolag
NACE code
6391 · Web search portal activities
Founded
10 december 2010
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-04-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas av Uhlén, Carl Erik Mathias i förening med en av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Utveckling och handhavande av internetbaserade databaser för biologisk information och därmed förenlig verksamhet.
Address
Solna
Email
contact@antibodypedia.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 152 | 119 | 91 | 63 | 3 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 122 | 94 | 43 | 16 | −24 |
| Depreciation & amort. | −0 | −0 | −0 | — | — |
| EBIT | 122 | 94 | 43 | 16 | −24 |
| Net financials | — | — | 3 | 23 | 23 |
| Profit before tax | 122 | 94 | 46 | 39 | −1 |
| Tax | −0 | −0 | −0 | — | — |
| Net profit | 122 | 94 | 46 | 39 | −1 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1 227 | 1 321 | 1 366 | 1 416 | 1 414 |
| Equity | 1 225 | 1 320 | 1 366 | 1 404 | 1 404 |
| Long-term debt | 0 | 0 | 0 | — | — |
| Short-term debt | 1 | 2 | 1 | 11 | 11 |
| Total debt | 1 | 2 | 1 | 11 | 11 |
EBITDA margin
-851.9%
This company
15.8%
Market median
-5492% vs market
20212025
Equity ratio
99.3%
This company
38.2%
Market median
+160% vs market
20212025
Return on equity
-0.0%
This company
18.4%
Market median
-100% vs market
20212025
Net profit margin
-21.4%
This company
8.1%
Market median
-364% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-05-01 – 2021-04-30
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
KV Chief Executive Officer | Chief Executive Officer | 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2020 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Antibodypedia AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kalle Von Feilitzen | Chief Executive Officer | 0 companies |
| Carl Erik Mathias Uhlén | Chairman | 0 companies |
| Erik Olof Björling | Board of Directors | 0 companies |